2019 Annual Meeting ASRS, Chicago, IL (US)

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

14th Meeting of EUNOS, Porto, Portugal

2019 SOE Congress, European Society of Ophthalmology, Nice, France

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York

KOL Event to present Phase 3 REVERSE&RESCUE results of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON), New York City

GenSight Biologics reports positive 96-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa